

Treatment Of Insulin Resistance

S Kalra, B Kalra, P Batra

Citation

S Kalra, B Kalra, P Batra. *Treatment Of Insulin Resistance*. The Internet Journal of Geriatrics and Gerontology. 2009 Volume 5 Number 2.

Abstract

Sufficient evidence is available to suggest that reducing insulin resistance may be beneficial, independent of a glucose –lowering effect.

It is uncertain however, when one should start pharmacological treatment of insulin resistance, and for how long it should be prescribed. It is also difficult to assess insulin sensitivity directly in clinical practice. Most tests for insulin sensitivity are invasive or unstandardized, and clinicians are forced to rely on surrogate end points.

In spite of these limitations, however, there is a consensus that insulin resistance should be treated aggressively. This review will focus only on anti diabetic medications in the treatment of insulin resistance.

CLASSIFICATION: DRUG TREATMENT OF INSULIN RESISTANCE

1. ANTI-DIABETIC DRUGS

- a. Non- Pharmacological
- c. diet
- d. exercise
- e. yoga

1. Pharmacological

- 1. Insulin sensitizers
- 3. metformin
- 4. thiazolidinediones
- 6. rosiglitazone
- 7. pioglitazone

1. Incretin – based therapies

3. GLP -1 analogues

5. liraglutide

1. DPP (IV) inhibitors

3. vildagliptin

4. sitagliptin

5. saxagliptin

1. Alpha glucosidase inhibitors

3. acarbose

4. voglibose

1. STATINS

2. ANGIOTENSIN CONVERTING ENZYME

3. INHIBITORS ARBS

4. ANTI-OBESITY DRUGS

GLITAZONES

Both pioglitazone and rosiglitazone raise HDL cholesterol (1, 2), change small, dense, more atherogenic LDL to larger, less atherogenic particles (3,4), and lower triglycerides (1,2), Rosiglitazone also reduces blood pressure, proportional to its effect on lowering insulin resistance (5).

The drug also lowers plasminogen activator inhibitor -1 levels, C- reactive protein (CRP) (5), E, selectin (7) and matrix –degrading metallo- proteinase (MMP-9)(8).

Pioglitazone lowers CRP in patients who do not exhibit glucose –lowering effect with the drug (6).

Pioglitazone has been shown to decrease intima –media

thickness of the carotid artery (9) and pulse wave velocity (6), irrespective of glycemic –lowering effect. These markers correlate well with atherosclerosis and vascular damage.

Rosiglitazone also improves endothelial function (10) and myocardial blood flow (11), the latter effect being noted only in type 2 diabetes of shorter duration.

Type 2 diabetic patients with coronary stents exhibit a reduced re stenosis rate when prescribed rosiglitazone or pioglitazone, even in the absence of glycemic difference (12, 13).

METFORMIN

The UKPDS showed that metformin is particularly effective in overweight type 2 diabetes subjects, a condition usually characterized by insulin resistance (14). Moreover, in essentially all clinical studies the improvement of hyperglycemia with metformin occurred in the presence of unaltered or reduced plasma insulin concentrations (15, 16). Taken collectively, these findings indicate the potential of metformin as an insulin –mimetic drug.

Metformin has no effect on the pancreatic β - cell stimulating insulin secretion (17). Mild increases in glucose –stimulated insulin secretion after metformin treatment (18) are thought to be the result of reduced glucose toxicity on the β – cell secondary to improved glycemic control (19).

In patients with type 2 diabetes, metformin has been shown to inhibit endogenous glucose production in most studies (20-22). This could be accounted for largely by inhibition of gluconeogenesis (23) , although an additional inhibitory effect of metformin on glycogen breakdown is likely (23,24).

Many (25, 27, 28), but not all, studies (26) using the hyperinsulinemic –euglycemic clamp technique have shown that metformin certainly –induced increase in insulin stimulated glucose disposal in patients with type 2 diabetes (20,22) . Since muscle represents a major site of insulin –mediated glucose uptake (19), metformin certainly have an insulin –like or insulin –sensitizing effect on this tissue.

Requirements of exogenous insulin are reduced (by \approx 30%) by addition of metformin in obese patients with type 2 diabetes (25-26) and in some patients with type 1, diabetes in whom glycemic control was unaltered (21,28).

While metformin improves insulin sensitivity in muscle, it

does not affect the antilipolytic action of insulin on adipose tissue (29). The overall effect of metformin on body weight is attributed to a reduction in caloric intake (25,30) rather than an increase in energy expenditure (31). Since reduction in body weight per se reduces insulin resistance, this may also represent mechanism by which metformin improves insulin resistance.

ALPHA GLUCOSIDASE INHIBITORS

Laube et al, 32 has reported that 12 weeks of acarbose treatment (100 mg three times daily) increased steady –state glucose infusion rate (SSGIR) by 45 %. In addition, Shinozaki et al. (33) treated subjects with IGT with voglibose (0.2mg three times daily), for 12 weeks, and showed that SSPG levels decreased significantly after voglibose treatment. These data suggest that α –glucosidase inhibitors improve insulin sensitivity in subjects with IGT and hyperinsulinemia possibly secondary to an amelioration of glucose –induced insulin resistance by reducing postprandial hyperglycemia. In contrast to studies in subjects with IGT, studies examining the effect of α glucosidase inhibitors or insulin sensitivity in patients with type 2 diabetes showed no amelioration of insulin resistance despite decreased postprandial glycemia (34-38). Thus, these data are in support of the notion that α glucosidase inhibitors improve insulin sensitivity in subjects with IGT but have no effect on insulin sensitivity in subjects with over type 2 diabetes.

GLP -1 AGONISTS

Decline of beta-cell sensitivity to glucose is an early defect of beta –cell function in type 2 diabetes. Liraglutide has been shown to restore beta –cell sensitivity to glucose [39]. The effect of exenatide on beta –cell sensitivity to glucose was assessed by measuring C-peptide levels during a hyperglycemic clamp in a study of 10 insulin– naïve patients with type 2 diabetes [40]. Fasting plasma C-peptide concentrations significantly increased from 0.75nmol/l before treatment \approx 0.83 nmol/l after exenatide treatment ($p<0.002$) following a hyper- glycaemic clamp.

Both liraglutide and vildagliptin ,have been shown to increase insulin sensitivity in obese candy –fit rats. Liraglutide also reduced weight, decreases calorie intake and shifts foot preference, but did not reduce energy expenditure in the animals. The weight loss was found to be associated with a change in fat man percentage (41, 42).

In LEAD -3 study, insulin resistance decreased by 0-65 %

with liraglutide 1.2 mg ($p=0.0249$ vs. glimepiride) and 1.35% with liraglutide 1.8 mg ($p=0.0011$ vs. glimepiride). This was associated with a reduction of weight in both liraglutide groups (2kg and 2.5 kg and 1.2 mg and 1.8 mg groups). Weight loss was apparent during the first 16 weeks, then remained stable upto 52 weeks, and was not related to nausea. Liraglutide also led to significant reductions in systolic blood pressure [43].

Thus, liraglutide has been shown to improve all components of the insulin resistance syndrome, when given as monotherapy.

Similar results have been reported to authors studying liraglutide in combination with metformin, glimepiride and insulin [44].

No episodes of major hypoglycemia have been reported with liraglutide monotherapy, and the incidence of minor hypoglycemia is low [44].

CONCLUSION

Many drugs are available for the management of insulin resistance. These drugs have beneficial effect only on glycemic parameters, but also on the other aspects of insulin resistance, such as weight, blood pressure and lipid profile. Metformin has been studied extensively, and remains the drug of choice for management of insulin resistance. Promising results signal a possible shift towards the use of liraglutide and other incretin –based therapies for the multifaceted treatment of insulin resistance.

This review should help treating physicians choose the appropriate therapy for patients with insulin resistance.

References

1. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, the Rosiglitazone Clinical Trials p. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. *J Clin Endocrinol Metab* 86:280-288, 2001.
2. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes : a 6- month randomized placebo – controlled dose –response study. *Diabetes Care* 23 : 1605 -1611,2000.
3. Freed MI, Macrovinia SM, Kreider MM Biswas N, Brunzell JD: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. *Am J Cardiol* 90:947 -952,2002.
4. Winkler K, Kornard T, Fullert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Weiland H, Marz Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension : a double- blind placebo –controlled study. *Diabetes Care* 26:2588-2594,2003.
5. Raji A, Seely EA, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. *Diabetes Care* 26 :172 -178,2003.
6. Satoh N, Ogawa Y, Usui T, Tagami T, Kohno S, Usegui H, Sugiyama H, Sugawara A, Yamada K, Shiimatsu A, Kuzuya H, Nakao K: Antiatherogenic effect of pioglitazone in type 2 diabetic patients, irrespective of the responsiveness to its antidiabetic effect. *Diabetes*
7. UK Prospective Diabetes Study Group 1998. Effect of intensive blood –glucose control with metformin on – complications in over – weight patients with type 2 diabetes (UKPDS 34.) *Lancet* 352 :854 -865.
8. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group. 1995 Efficacy of metformin in patients with non –insulin – dependent diabetes mellitus. *N Engl J Med* 333: 541-549.
9. Hermann LS, Kjellstrom T, Nillson –Ehle P 1991. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non –insulin - dependent diabetes mellitus.
10. Bailey CJ 1992 Biguanides and NIDDM. *Diabetes Care* 15 :755-772.
11. Dinneen S, Gerich J, Rizza R 1992. Carbohydrate metabolism in non – insulin dependent diabetes mellitus. *N Engl J Med* 327 :707 713.
12. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE 1995 Metabolic effects of metformin in non –insulin dependent diabetes mellitus. *N Engl J Med* .333:550 -554.
13. Jackson RA, Hawa MI, Jaspan JB, Sim BM. Disilvio L, Featherbe D, Kurtz AB. 1987. Mechanism of metformin action in non-insulin – dependent diabetes. *Diabetes* 36:632 -640.
14. DeFronzo RA, Barzilai N, Simonson DC 1991 Mechanism of metformin action in noninsulin – dependent diabetes. *Diabetes* 36 :632 -640.
15. Johnson AB , Webster JM, Sum C-F, Heseltine L, Argyraki M, Cooper BG, Taylor R 1993. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase

- activity in overweight type II diabetic patients. *Metabolism* 42 : 1217-1222.
16. Cusi K, Consoli A, DeFronzo RA 1996 Metabolic effects of metformin on glucose and lactate metabolism in non –insulin –dependent diabetes mellitus. *J Clin Endocrinol Metab* 81: 4059 -4067.
17. Prager R, Scherthaner G, Graf H 1986 Effect of metformin on peripheral insulin sensitivity in non –insulin –dependent diabetes mellitus. *Diabetes Metab* 12 :346-350.
18. Makimattilia S, Nikkila K, Yki –Jarvinen H 1999. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes. *Diabetologia* 42 : 406-412.
19. Robinson AC, Johnson DG, Bruke J, Eleles RS, Robinson S 1998. The effect of metformin on glycemic control and serum lipids in insulin –treated NIDDM patients with suboptimal metabolic control. *Diabetes Care* 21 : 701-705.
20. Gin H, Slama G, Weissbrodt P, Aubertin J 1985. Metformin improved insulin resistance in type 1, insulin dependent diabetic patients. *Metabolism* 34 : 923-925.
21. Pagano G, Tagliaferro V, Carta Q, Caselle MT, Bozzo C, vitelli F, Trovati M, Cocuzza E 1983. Metformin reduces insulin requirements in type 1 (insulin –dependent)diabetes. *Diabetologia* 24: 351-354.
22. Bellomo R, McGrath B, Boyce N 1991. In vivo catecholamine extraction during continuos hemofiltration in inotrope-dependent patients. *ASAIO Trans* 37 : M324 –M325.
23. Lee A, Morley JE 1998 Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin –dependent diabetes *Obes Res* 6:47-53.
24. Leslie A, Morlie JE 1998 . Energy expenditure in non –insulin dependent diabetic subjects on metformin or sulfonylurea therapy .*Clin Sci* 73 : 41-45.
25. Lauke H, Linn T, Heyen P. The effects of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. *Exp Clin Endocrinol Diabetes* 1998;106 :231-233.
26. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Horano Y 1996. Improvement of Insulin sensitivity and dyslipidemia with a new α -glucosidase inhibitor, voglibose, in non-diabetic hyperinsulinemic subjects. *Metabolism* 45:731-737.
27. Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, Scherthaner G 1989. Effects of 8-wk α -glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose-output and peripheral insulin sensitivity in poorly controlled type II diabetic patients. *Diabetes Care* 12 : 537 -543.
28. Raeven GM, Lardinois CK, Greenfield MS, Schwartz HC Vreman HJ 1990. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. *Diabetes Care* 13[Suppl 3]:32-36.
29. Jenney A, Proietto J, O'Dea K, Nankervis A, Traianedes K, in NIDDM patients without changes in insulin sensitivity. *Diabetes Care* 16:499 – 502.
30. Johnson AB, Taylor R 1996. Does suppression of postprandial blood glucose excursions by the α glucosidase inhibitor miglitol improve insulin sensitivity in diet –treated type II diabetic patients ? *Diabetes Care* 19: 559-563.
31. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, Tominago Y 1998 .Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non – insulin – treated NIDDM patients. *Diabetes Care* 21:256-260.
32. Chang AM, Jakobson G, Sturis J et al. The GLP -1 derivative N2211 restores β –cell sensitivity to glucose in type 2 diabetic patients after a single dose. *Diabetes* 2003; 52 : 1786-1791.
33. Egan JM, Meneily GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin -4 in type 2 diabetes. *AM J Physiol Endocrinol Metab* 2003; 284 : E1072 –E1079.
34. Raun K, von Voss P, gotfredsen CF, golozobovaV, Rolen B, Knudsen LB. Liraglutide, a long –acting glucagon-like peptide, a long acting glucagon –like peptide -1 analog, reduces body weight and food intake in obese candy –fed rats, whereas a dipedyl peptidase –IV inhibitor, vildagliptin, does not
35. Pospisilik JA, Stanfford SG, Demuth HU, McIntosh CH , and Pederson RA (2002 b) Long –term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF .Zucker rat : a euglycemic –hyperinsulinemic clamp Study.
36. Garber A, Henry R, Ratner R, et al. For the LEAD-3 (Mono) Study group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD – 3 Mono) : A randomized, 52 week, phase III, double –blind parallel treatment trial. *Lancet* 2009;373 (9962):473 -481.
37. Kalra S, Kalra B , Sharma A. Liraglutide – a novel GLP -1 analogue. *Recent Patients on Endocrine, Metabolic & Immune Drug Discovery* 2009;3: 200-204.

Author Information

Sanjay Kalra

Bharti Hospital

Bharti Kalra

Bharti Hospital

Pooja Batra

Bharti Hospital